Adolor Corp

Adolor — Technical Presentation (September 2006)

17 slides from Adolor's technical presentation, Sep 5, 2006

  1. Slide 1: oration. All rights reserved.

    Exhibit 99.2 © 2006 Adolor Corporation. All rights reserved.

  2. Slide 2: Forward-looking statements

    This oral presentation and the questions and answers that follow contain forward-looking statements, including, but not limited to, statements about: • our collaborator’s ability to receive FDA approval for use of Entereg® in chronic pain patients taking opioids • our ability to receive FDA approval

  3. Slide 3: Phase 3 clinical studies 012 and 013 evaluating Entereg for OBD

    Phase 3 clinical studies 012 and 013 evaluating Entereg® (alvimopan) for the treatment of opioid-induced bowel dysfunction (OBD) in chronic non-cancer pain September 5, 2006

  4. Slide 4: Overview of Study Design

    Primary Endpoint Spontaneous Bowel Movement Frequency Responders – Proportion of subjects with 3 or more SBMs/week where this is an increase of at least 1 SBM/week on average over baseline Study Design Randomized, double-blind, 12-weeks of treatment 2 doses of alvimopan (0.5mg QD and 0.5mg BID) and

  5. Slide 5: SBM Frequency Responders

    Weeks 1-12 *p<0.00001 vs. placebo * Study 012 Study 013 p=0.214 p=0.259 p=0.065 0 10 20 30 40 50 60 70 80 Placebo (n=172) Alvimopan 0.5mg QD (n=174) Alvimopan 0.5mg BID (n=172) 0 10 20 30 40 50 60 70 80 Placebo (n=164) Alvimopan 0.5mg QD (n=161) Alvimopan 0.5mg BID (n=160) SBM Frequency Responders L

  6. Slide 6: Weekly SBM Frequency Responders - Study 012

    20 30 40 50 60 70 80 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Placebo (n=172) Alvimopan 0.5mg QD (n=174) Alvimopan 0.5mg BID (n=172) Week Study 012 Week Treatment Follow- up Weekly SBM Frequency Responders LOCF LOCF p<0.004 for alvimopan 0.5mg BID vs. placebo during treatment p<0.004 for alvimopan 0.5mg B

  7. Slide 7: Weekly SBM Frequency Responders - Study 013

    20 30 40 50 60 70 80 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Placebo (n=164) Alvimopan 0.5mg QD (n=161) Alvimopan 0.5mg BID (n=160) Week Study 013 Week Treatment Follow- up Weekly SBM Frequency Responders LOCF LOCF p<0.05 for alvimopan 0.5mg BID vs. placebo at weeks 1, 3, 9 p<0.05 for alvimopan 0.5mg BID

  8. Slide 8: Weekly SBM Frequency Responders

    20 30 40 50 60 70 80 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Study 012 (n=172) Study 013 (n=160) Week Alvimopan 0.5mg BID Week Treatment Follow- up Weekly SBM Frequency Responders LOCF LOCF

  9. Slide 9: Change in Weekly SBM Frequency

    Weeks 1-12 *p &#60; 0.005 vs. placebo < 0.005 vs. placebo 0.005 vs. placebo * Study 012 Study 013 * * * 0 1 2 3 4 5 Placebo (n=172) Alvimopan 0.5mg QD (n=174) Alvimopan 0.5mg BID (n=172) 0 1 2 3 4 5 Placebo (n=164) Alvimopan 0.5mg QD (n=161) Alvimopan 0.5mg BID (n=160) Change in Weekly SBM Frequency

  10. Slide 10: Summary of Safety Findings from Studies 012 and 013

    There was no effect on pain and/or analgesia as assessed by changes in opioid use or visual analog pain scores Alvimopan was generally well tolerated in studies 012 & 013 with a safety and tolerability profile comparable to placebo – Most frequently reported AEs were GI related, including abdominal

  11. Slide 11: Implications of Results of Studies 012 and 013

    Study 012 achieved its primary endpoint in patients treated with alvimopan 0.5mg BID (p=<0.001) – Confirms positive results of phase 2b study 011 in both responder analysis and secondary endpoint of change in average weekly SBMs Study 013 confirms results seen in studies 011 and 012 on the secondary

  12. Slide 12: Phase IIb study 008 in chronic cancer pain patients

    A randomized, double-blind, placebo-controlled, multicenter phase IIb study (767905/008) to evaluate the efficacy and safety of Entereg (alvimopan) for the treatment of opioid-induced bowel dysfunction in chronic cancer pain patients

  13. Slide 13: Overview of Study Design

    Primary Endpoint Change from baseline in average weekly SCBM frequency – SCBM defined as bowel movement with no laxative use in the previous 24 hours that provided the subject with a feeling of complete evacuation Study Design Randomized, double-blind, 3 weeks of treatment – 3 alvimopan doses (0.5mg

  14. Slide 14: Study 008 Change in Weekly SCBM Frequency

    2.14 0 1 2 3 Placebo (N=71) Alvimopan 0.5mg BID (N=68) Alvimopan 1mg QD (N=27) Alvimopan 1mg BID (N=67) Weeks 1-3 LOCF 1.9 1.55 1.76 Study 008 Change in Weekly SCBM Frequency LOCF

  15. Slide 15: Study 008 Change in Weekly SBM Frequency

    3.08 0 1 2 3 Placebo (N=71) Alvimopan 0.5mg BID (N=68) Alvimopan 1mg QD (N=27) Alvimopan 1mg BID (N=67) Weeks 1-3 LOCF * p<0.05 vs. placebo * * 2.82 1.6 2.7 Study 008 Change in Weekly SBM Frequency LOCF * p<0.05 vs. placebo

  16. Slide 16: Implications of Study 008 results

    Taken together with the results of other studies of alvimopan, study 008 supports the findings of potential benefit in the chronic cancer pain population Safety and tolerability profile similar to placebo and consistent with observations in other studies of alvimopan in chronic non-cancer pain patie

  17. Slide 17: oration. All rights reserved.

    © 2006 Adolor Corporation. All rights reserved.

Adolor — Technical Presentation (September 2006) on 6ix